$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

$capr Overview Financials Valuation SEC Filings Company Website

2015 Q3 Form 10-Q Financial Statement

#000114420415049296 Filed on August 14, 2015

Income Statement

Concept	2015 Q3	2015 Q2	2014 Q2
Revenue	$1.315M	$1.291M	$1.042M
YoY Change	1.03%	23.98%	449.66%
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$970.0K	$930.0K	$660.0K
YoY Change	18.29%	40.91%	34.69%
% of Gross Profit
Research & Development	$3.193M	$3.427M	$1.856M
YoY Change	62.32%	84.6%	41.51%
% of Gross Profit
Depreciation & Amortization	$30.00K	$30.00K	$10.00K
YoY Change	200.0%	200.0%
% of Gross Profit
Operating Expenses	$4.165M	$4.353M	$2.522M
YoY Change	49.48%	72.6%	39.76%
Operating Profit	-$2.851M	-$3.062M	-$1.480M
YoY Change	91.94%	106.81%	-8.34%
Interest Expense	$61.68K	$61.68K	$54.70K
YoY Change	2.65%	12.75%	780.76%
% of Operating Profit
Other Income/Expense, Net	-$61.39K	-$61.53K	-$53.51K
YoY Change	4.26%	14.98%	464.25%
Pretax Income	-$2.910M	-$3.120M	-$1.530M
YoY Change	88.96%	103.92%	-5.56%
Income Tax			$0.00
% Of Pretax Income
Net Earnings	-$2.912M	-$3.123M	-$1.534M
YoY Change	88.6%	103.6%	-5.58%
Net Earnings / Revenue	-221.46%	-241.83%	-147.26%
Basic Earnings Per Share
Diluted Earnings Per Share	-$1.796M	-$1.926M	-$1.297M
COMMON SHARES
Basic Shares Outstanding	16.25M shares		11.69M shares
Diluted Shares Outstanding

Balance Sheet

Concept	2015 Q3	2015 Q2	2014 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$17.22M	$20.53M	$11.91M
YoY Change	69.96%	72.43%	5077.38%
Cash & Equivalents	$4.218M	$5.038M	$11.58M
Short-Term Investments	$13.00M	$15.49M	$325.8K
Other Short-Term Assets	$90.00K	$730.0K	$4.500M
YoY Change	-97.64%	-83.78%	7400.0%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$17.71M	$21.64M	$16.41M
YoY Change	24.78%	31.89%	5572.45%
LONG-TERM ASSETS
Property, Plant & Equipment	$332.1K	$263.1K	$204.0K
YoY Change	47.92%	28.95%	20423.44%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$130.0K	$70.00K	$60.00K
YoY Change	116.67%	16.67%	1223.04%
Total Long-Term Assets	$2.169M	$2.048M	$2.027M
YoY Change	3.93%	1.01%	36569.45%
TOTAL ASSETS
Total Short-Term Assets	$17.71M	$21.64M	$16.41M
Total Long-Term Assets	$2.169M	$2.048M	$2.027M
Total Assets	$19.88M	$23.69M	$18.44M
YoY Change	22.11%	28.49%	6153.76%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.890M	$3.220M	$2.180M
YoY Change	51.31%	47.71%	448.32%
Accrued Expenses			$140.0K
YoY Change			-60.0%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change			-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$6.534M	$6.863M	$6.492M
YoY Change	5.52%	5.72%	539.26%
LONG-TERM LIABILITIES
Long-Term Debt	$9.160M	$9.160M	$8.640M
YoY Change	0.0%	6.02%
Other Long-Term Liabilities	$2.270M	$3.120M	$6.390M
YoY Change	-58.04%	-51.17%	1152.94%
Total Long-Term Liabilities	$11.42M	$12.27M	$15.03M
YoY Change	-21.56%	-18.35%	2847.03%
TOTAL LIABILITIES
Total Short-Term Liabilities	$6.534M	$6.863M	$6.492M
Total Long-Term Liabilities	$11.42M	$12.27M	$15.03M
Total Liabilities	$17.96M	$19.14M	$21.52M
YoY Change	-13.48%	-11.09%	1308.82%
SHAREHOLDERS EQUITY
Retained Earnings	-$31.83M
YoY Change
Common Stock	$33.74M	$33.46M	$15.76M
YoY Change	111.98%	112.34%	36496.79%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$1.926M	$4.555M	-$3.085M
YoY Change
Total Liabilities & Shareholders Equity	$19.88M	$23.69M	$18.44M
YoY Change	22.11%	28.49%	6153.76%

Cashflow Statement

Concept	2015 Q3	2015 Q2	2014 Q2
OPERATING ACTIVITIES
Net Income	-$2.912M	-$3.123M	-$1.534M
YoY Change	88.6%	103.6%	-5.58%
Depreciation, Depletion And Amortization	$30.00K	$30.00K	$10.00K
YoY Change	200.0%	200.0%
Cash From Operating Activities	-$3.240M	-$1.880M	-$6.010M
YoY Change	45.29%	-68.72%	853.97%
INVESTING ACTIVITIES
Capital Expenditures	-$90.00K	-$20.00K	-$60.00K
YoY Change	28.57%	-66.67%	20.0%
Acquisitions
YoY Change
Other Investing Activities	$2.500M	$0.00	$0.00
YoY Change			-100.0%
Cash From Investing Activities	$2.420M	-$30.00K	-$70.00K
YoY Change	-3557.14%	-57.14%	-107.22%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	10.00K	0.000	4.690M
YoY Change	-98.08%	-100.0%
NET CHANGE
Cash From Operating Activities	-3.240M	-1.880M	-6.010M
Cash From Investing Activities	2.420M	-30.00K	-70.00K
Cash From Financing Activities	10.00K	0.000	4.690M
Net Change In Cash	-810.0K	-1.910M	-1.390M
YoY Change	-54.49%	37.41%	-508.82%
FREE CASH FLOW
Cash From Operating Activities	-$3.240M	-$1.880M	-$6.010M
Capital Expenditures	-$90.00K	-$20.00K	-$60.00K
Free Cash Flow	-$3.150M	-$1.860M	-$5.950M
YoY Change	45.83%	-68.74%	925.86%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
	dei	Entity Filer Category EntityFilerCategory	Smaller Reporting Company
	dei	Trading Symbol TradingSymbol	CAPR
CY2015Q3	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	16254985	shares
CY2015Q2	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	15494365	USD
CY2014Q4	us-gaap	Marketable Securities Current MarketableSecuritiesCurrent	0	USD
	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2014Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	235523	USD
	dei	Entity Central Index Key EntityCentralIndexKey	0001133869
CY2015Q2	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	130724	USD
CY2014Q4	us-gaap	Assets Current AssetsCurrent	11607545	USD
CY2015Q2	us-gaap	Assets Current AssetsCurrent	21642939	USD
CY2014Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	229455	USD
CY2015Q2	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	263059	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	239752	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Net FiniteLivedIntangibleAssetsNet	215377	USD
CY2014Q4	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	2977024	USD
CY2015Q2	us-gaap	Restricted Cash And Cash Equivalents At Carrying Value RestrictedCashAndCashEquivalentsAtCarryingValue	599582	USD
CY2014Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	360233	USD
CY2015Q2	us-gaap	Grants Receivable Current GrantsReceivableCurrent	380008	USD
CY2014Q4	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1500000	USD
CY2015Q2	us-gaap	Other Intangible Assets Net OtherIntangibleAssetsNet	1500000	USD
CY2014Q4	us-gaap	Other Assets OtherAssets	55320	USD
CY2015Q2	us-gaap	Other Assets OtherAssets	69455	USD
CY2014Q4	us-gaap	Assets Assets	13632072	USD
CY2015Q2	us-gaap	Assets Assets	23690830	USD
CY2014Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	1699254	USD
CY2015Q2	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	2678848	USD
CY2014Q4	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	433712	USD
CY2015Q2	capr	Accounts Payable And Accrued Expenses Related Party Current AccountsPayableAndAccruedExpensesRelatedPartyCurrent	538721	USD
CY2014Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	4166667	USD
CY2015Q2	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	3645834	USD
CY2014Q4	us-gaap	Liabilities Current LiabilitiesCurrent	6299633	USD
CY2015Q2	us-gaap	Liabilities Current LiabilitiesCurrent	6863403	USD
CY2014Q4	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	4166666	USD
CY2015Q2	us-gaap	Deferred Revenue Noncurrent DeferredRevenueNoncurrent	2734374	USD
CY2014Q4	us-gaap	Long Term Loans Payable LongTermLoansPayable	9155857	USD
CY2015Q2	us-gaap	Long Term Loans Payable LongTermLoansPayable	9155857	USD
CY2014Q4	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	258639	USD
CY2015Q2	us-gaap	Interest Payable Current And Noncurrent InterestPayableCurrentAndNoncurrent	382001	USD
CY2014Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	13581162	USD
CY2015Q2	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	12272232	USD
CY2014Q4	us-gaap	Liabilities Liabilities	19880795	USD
CY2015Q2	us-gaap	Liabilities Liabilities	19135635	USD
CY2014Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2015Q2	us-gaap	Preferred Stock Value PreferredStockValue	0	USD
CY2014Q4	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	16054697	USD
CY2015Q2	us-gaap	Additional Paid In Capital Common Stock AdditionalPaidInCapitalCommonStock	33446837	USD
CY2014Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	0	USD
CY2015Q2	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	6535	USD
CY2014Q4	us-gaap	Stockholders Equity StockholdersEquity	-6248723	USD
CY2015Q2	us-gaap	Stockholders Equity StockholdersEquity	4555195	USD
	dei	Entity Registrant Name EntityRegistrantName	CAPRICOR THERAPEUTICS, INC.
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	106	USD
CY2015Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	16222754	shares
	capr	Collaboration Revenue CollaborationRevenue	1953125	USD
	capr	Collaboration Revenue CollaborationRevenue	2083334	USD
	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
	us-gaap	Revenue From Grants RevenueFromGrants	1126243	USD
	us-gaap	Revenues Revenues	2083334	USD
	us-gaap	Revenues Revenues	3079368	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3236877	USD
	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7233891	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1512895	USD
	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	2321819	USD
CY2014Q2	capr	Collaboration Revenue CollaborationRevenue	1041667	USD
CY2014Q2	us-gaap	Revenue From Grants RevenueFromGrants	0	USD
CY2014Q2	us-gaap	Revenues Revenues	1041667	USD
CY2015Q2	us-gaap	Revenues Revenues	1291466	USD
CY2015Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	3426803	USD
CY2014Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	665728	USD
CY2015Q2	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	926279	USD
CY2014Q2	us-gaap	Operating Expenses OperatingExpenses	2522088	USD
CY2015Q2	us-gaap	Operating Expenses OperatingExpenses	4353082	USD
CY2014Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-1480421	USD
CY2015Q2	us-gaap	Operating Income Loss OperatingIncomeLoss	-3061616	USD
CY2014Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1196	USD
CY2015Q2	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	156	USD
CY2014Q2	us-gaap	Interest Expense InterestExpense	54704	USD
CY2014Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-53508	USD
CY2015Q2	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-61525	USD
CY2014Q2	us-gaap	Net Income Loss NetIncomeLoss	-1533929	USD
CY2015Q2	us-gaap	Net Income Loss NetIncomeLoss	-3123141	USD
CY2014Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	-470	USD
CY2015Q2	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	10475	USD
CY2014Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-1534399	USD
CY2015Q2	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-3112666	USD
CY2014Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.13
CY2015Q2	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.19
	us-gaap	Operating Expenses OperatingExpenses	4749772	USD
	us-gaap	Operating Expenses OperatingExpenses	9555710	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-2666438	USD
	us-gaap	Operating Income Loss OperatingIncomeLoss	-6476342	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	1919	USD
	us-gaap	Investment Income Interest And Dividend InvestmentIncomeInterestAndDividend	431	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-78112	USD
	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	-122931	USD
	us-gaap	Net Income Loss NetIncomeLoss	-2744550	USD
	us-gaap	Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax	6535	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.23
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	15549988	shares
CY2014Q2	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	11582186	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-6592738	USD
	us-gaap	Earnings Per Share Basic And Diluted EarningsPerShareBasicAndDiluted	-0.42
	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11690888	shares
CY2014Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	13632072	USD
CY2015Q2	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	23690830	USD
CY2015Q2	us-gaap	Common Stock Value CommonStockValue	16223	USD
CY2014Q4	us-gaap	Common Stock Value CommonStockValue	11707	USD
CY2015Q2	capr	Collaboration Revenue CollaborationRevenue	911458	USD
CY2015Q2	us-gaap	Revenue From Grants RevenueFromGrants	380008	USD
CY2014Q2	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	1856360	USD
CY2015Q2	us-gaap	Interest Expense InterestExpense	61681	USD
CY2014Q2	us-gaap	Weighted Average Number Of Share Outstanding Basic And Diluted WeightedAverageNumberOfShareOutstandingBasicAndDiluted	11692318	shares
	us-gaap	Net Income Loss NetIncomeLoss	-6599273	USD
	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-2744444	USD
	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	16446218	USD
	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	35387	USD
	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	915051	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	16216	USD
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	51004	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	192206	USD
	us-gaap	Share Based Compensation ShareBasedCompensation	915051	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	2976441	USD
	us-gaap	Increase Decrease In Restricted Cash For Operating Activities IncreaseDecreaseInRestrictedCashForOperatingActivities	-2377442	USD
	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	0	USD
	capr	Increase Decrease From Grants Receivable IncreaseDecreaseFromGrantsReceivable	19775	USD
	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-99659	USD
	capr	Increase Decrease In Prepaid And Other Current Assets IncreaseDecreaseInPrepaidAndOtherCurrentAssets	-104799	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	29592	USD
	us-gaap	Increase Decrease In Deposits Outstanding IncreaseDecreaseInDepositsOutstanding	14135	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	196574	USD
	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	979594	USD
	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	76098	USD
	capr	Increase Decrease In Accounts Payable And Accrued Expenses Related Party IncreaseDecreaseInAccountsPayableAndAccruedExpensesRelatedParty	105009	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	80031	USD
	us-gaap	Increase Decrease In Interest Payable Net IncreaseDecreaseInInterestPayableNet	123362	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	10416666	USD
	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-1953125	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	5326867	USD
	us-gaap	Net Cash Provided By Used In Operating Activities Continuing Operations NetCashProvidedByUsedInOperatingActivitiesContinuingOperations	-3930047	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Marketable Securities PaymentsToAcquireMarketableSecurities	15487830	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	809	USD
	us-gaap	Proceeds From Sale And Maturity Of Marketable Securities ProceedsFromSaleAndMaturityOfMarketableSecurities	0	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	116456	USD
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	50760	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-163301	USD
	us-gaap	Net Cash Provided By Used In Investing Activities Continuing Operations NetCashProvidedByUsedInInvestingActivitiesContinuingOperations	-15548063	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	4689083	USD
	us-gaap	Net Cash Provided By Used In Financing Activities Continuing Operations NetCashProvidedByUsedInFinancingActivitiesContinuingOperations	16481605	USD
CY2013Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	1729537	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Interest Paid InterestPaid	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	0	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	23910	USD
	us-gaap	Payments For Proceeds From Other Investing Activities PaymentsForProceedsFromOtherInvestingActivities	0	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	35387	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	1658822	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	4.25
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	10000000	USD
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	9473	USD
	us-gaap	Payments For Capital Improvements PaymentsForCapitalImprovements	23744	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	-2996505	USD
	us-gaap	Cash And Cash Equivalents Period Increase Decrease CashAndCashEquivalentsPeriodIncreaseDecrease	9852649	USD
	us-gaap	Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions	2469	USD
CY2015Q2	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	20500000	USD
CY2014Q4	capr	Cash Cash Equivalents And Marketable Securities CashCashEquivalentsAndMarketableSecurities	8000000	USD
CY2015Q1	us-gaap	Stock Issued During Period Shares New Issues StockIssuedDuringPeriodSharesNewIssues	2839045	shares
CY2015Q1	us-gaap	Sale Of Stock Price Per Share SaleOfStockPricePerShare	3.523
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	24375	USD
	us-gaap	Amortization Of Intangible Assets AmortizationOfIntangibleAssets	5832	USD
	us-gaap	Research And Development In Process ResearchAndDevelopmentInProcess	1500000	USD
CY2015Q2	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	16223281	shares
CY2014Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11707051	shares
CY2014Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11707051	shares
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	4686614	USD
	us-gaap	Proceeds From Issuance Of Long Term Debt ProceedsFromIssuanceOfLongTermDebt	0	USD
CY2015Q1	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	7050000	USD
CY2015Q2	us-gaap	Marketable Securities MarketableSecurities	15494365	USD
CY2015Q2	us-gaap	Deferred Finance Costs Noncurrent Net DeferredFinanceCostsNoncurrentNet	30000	USD
CY2014Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	303881	shares
	capr	Class Of Warrant Or Right Granted ClassOfWarrantOrRightGranted	0	shares
	capr	Class Of Warrant Or Right Expired ClassOfWarrantOrRightExpired	-52650	shares
CY2014Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	10.02
	capr	Class Of Warrant Or Right Granted Weighted Average Exercise Price ClassOfWarrantOrRightGrantedWeightedAverageExercisePrice	0
	capr	Class Of Warrant Or Right Expired Weighted Average Exercise Price ClassOfWarrantOrRightExpiredWeightedAverageExercisePrice	47.00
	capr	Class Of Warrant Or Right Exercised ClassOfWarrantOrRightExercised	15401	shares
	capr	Class Of Warrant Or Right Exercised Weighted Average Exercise Price ClassOfWarrantOrRightExercisedWeightedAverageExercisePrice	2.27
CY2015Q2	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	2.27
CY2015Q2	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	235830	shares
CY2015Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	3.53
CY2014Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.05
CY2015Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	342930	USD
CY2014Q2	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	107662	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	906463	USD
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	192206	USD
CY2015Q2	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	4600000	USD
	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P3Y4M24D
CY2015Q2	us-gaap	Cash Uninsured Amount CashUninsuredAmount	20600000	USD
CY2015Q2	capr	Leases Monthly Payments For First Twelve Months LeasesMonthlyPaymentsForFirstTwelveMonths	16620	USD
CY2015Q2	capr	Leases Monthly Payments For Second Twelve Months LeasesMonthlyPaymentsForSecondTwelveMonths	17285	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	17957	USD
CY2015Q1	us-gaap	Operating Leases Rent Expense Net OperatingLeasesRentExpenseNet	21420	USD
	us-gaap	Payments For Royalties PaymentsForRoyalties	20000	EUR
CY2015Q2	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	74305	USD
CY2014Q4	us-gaap	Finite Lived Intangible Assets Accumulated Amortization FiniteLivedIntangibleAssetsAccumulatedAmortization	49930	USD
CY2015Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2014Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	5000000	shares
CY2015Q2	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	0	shares
CY2015Q2	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2014Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2015Q2	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2014Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.001
CY2015Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
CY2014Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	50000000	shares
	us-gaap	Use Of Estimates UseOfEstimates	<div style="MARGIN: 0pt 0px; FONT: 10pt Times New Roman, Times, Serif "> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;MARGIN: 0in 0in 0pt"> <u><font style="FONT-SIZE: 10pt">Use of Estimates</font></u></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt 0.25in"> <font style="FONT-SIZE: 10pt"> </font></div> <div style="CLEAR:both; FONT-FAMILY:Times New Roman;FONT-SIZE: 10pt;TEXT-INDENT: 0.5in; MARGIN: 0in 0in 0pt" align="justify"><font style="FONT-SIZE: 10pt">The preparation of financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the condensed consolidated financial statements. Estimates also affect the reported amounts of revenues and expenses during the reporting period. Management uses its historical records and knowledge of its business in making these estimates. Accordingly, actual results may differ from these estimates.</font></div> </div><table border="0" style="width:100%; table-layout:fixed;" cellspacing="0" cellpadding="0"><tr><td></td></tr></table>
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Next Twelve Months FiniteLivedIntangibleAssetsAmortizationExpenseNextTwelveMonths	24375	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Two FiniteLivedIntangibleAssetsAmortizationExpenseYearTwo	48749	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Three FiniteLivedIntangibleAssetsAmortizationExpenseYearThree	48749	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Four FiniteLivedIntangibleAssetsAmortizationExpenseYearFour	43732	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense Year Five FiniteLivedIntangibleAssetsAmortizationExpenseYearFive	43276	USD
CY2015Q2	us-gaap	Finite Lived Intangible Assets Amortization Expense After Year Five FiniteLivedIntangibleAssetsAmortizationExpenseAfterYearFive	6496	USD
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P7Y
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.022	pure
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due Current OperatingLeasesFutureMinimumPaymentsDueCurrent	248766	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Two Years OperatingLeasesFutureMinimumPaymentsDueInTwoYears	364866	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due In Three Years OperatingLeasesFutureMinimumPaymentsDueInThreeYears	96750	USD
CY2015Q2	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	710382	USD
CY2014Q1	capr	Proceeds From Development Fee ProceedsFromDevelopmentFee	12500000	USD
CY2013Q4	capr	Additional Milestone Payments To Be Received Contingent Upon Exercise Of Options AdditionalMilestonePaymentsToBeReceivedContingentUponExerciseOfOptions	325000000	USD
CY2013Q4	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-50
CY2015Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6143299	shares
CY2014Q2	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5193021	shares
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	5193021	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.15
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	4.92
	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	6143299	shares

Files In Submission

Name	View Source	Status
0001144204-15-049296-index-headers.html	Edgar Link	pending
0001144204-15-049296-index.html	Edgar Link	pending
0001144204-15-049296.txt	Edgar Link	pending
0001144204-15-049296-xbrl.zip	Edgar Link	pending
capr-20150630.xml	Edgar Link	completed
capr-20150630.xsd	Edgar Link	pending
capr-20150630_cal.xml	Edgar Link	unprocessable
capr-20150630_def.xml	Edgar Link	unprocessable
capr-20150630_lab.xml	Edgar Link	unprocessable
capr-20150630_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
Financial_Report.xlsx	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
v417053_10q.htm	Edgar Link	pending
v417053_ex10-1.htm	Edgar Link	pending
v417053_ex10-2.htm	Edgar Link	pending
v417053_ex10-3.htm	Edgar Link	pending
v417053_ex31-1.htm	Edgar Link	pending
v417053_ex31-2.htm	Edgar Link	pending
v417053_ex32-1.htm	Edgar Link	pending
v417053_ex32-2.htm	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr

2015 Q3 Form 10-Q Financial Statement

#000114420415049296 Filed on August 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR CAPRICOR THERAPEUTICS, INC. Stock $capr

2015 Q3 Form 10-Q Financial Statement

#000114420415049296 Filed on August 14, 2015

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CAPR
CAPRICOR THERAPEUTICS, INC. Stock $capr